When cancer starts in the uterus, it is called uterine cancer. The uterus is the pear-shaped organ in a woman's pelvis (the area below your stomach and in between your hip bones). The uterus, also called the womb, is where the baby grows when a woman is pregnant. The most common type of uterine cancer is also called endometrial cancer because it forms in the lining of your uterus, called the endometrium.
When uterine cancer is found early, treatment is most effective. The most common sign of uterine cancer is bleeding that is not normal for you because of when it happens or how heavy it is. This could mean bleeding, even a little bit, after you have gone through menopause; periods that are longer than seven days; bleeding between periods; or any other bleeding that is longer or heavier than is normal for you.
Other symptoms, such as pain or pressure in your pelvis, also may occur if you have uterine cancer. If you have any of these symptoms, talk to your doctor, nurse, or other health care professional right away. They may be caused by something other than cancer, but the only way to know is to see your health care professional.
No single gene causes uterine cancer, the fourth most common cancer among women, which is on the rise in the U.S.
Tammy Kaminski can still recall the taste of benzene, a carcinogenic byproduct of burning jet fuel. For nine months after the 9/11 attacks, she volunteered for eight hours every Saturday at St. Paul's Chapel, just around the corner from ground zero in New York City.
A team of scientists led by the University of Michigan Health Rogel Cancer Center has found that a class of U.S. Food and Drug Administration-approved drugs can effectively stop a highly aggressive type of uterine cancer in its tracks, paving a quick path toward new treatment strategies for a deadly cancer with limited therapeutic options.
New research being presented at The European Congress on Obesity (ECO) held online this year, suggests that a measure of body shape should be used alongside body mass index (BMI) to help determine the risk of obesity-related cancers.
In a new study, Yale Cancer Center researchers have defined the genetic landscape of uterine leiomyosarcomas (uLMS).
Researchers at Baylor College of Medicine show that analysis of the proteomics, or all the protein data, from aggressive human cancers is a useful approach to identify potential novel therapeutic targets.
When her gynecologist recommended genetic testing, Mai Tran was reluctant.
A new type of breast cancer drug developed by researchers at the University of Illinois Chicago can help halt progression of disease and is not toxic, according to phase 1 clinical trials. The drug is specifically designed for women whose cancer has stopped responding to hormone therapy.
In an article that was just published in Proceedings of the National Academy of Sciences by the group of Dr. Manel Esteller, is solved this mystery by describing that in cancer cells the protein that generates the nucleotide "Y" is epigenetically inactivated, causing small but highly aggressive tumors.
The cover for issue 29 of Oncotarget features, "In vivo effects of treatment with L-Grb2 in combination with anti-angiogenic therapy in an ovarian tumor model," by Lara, et al. which reported that adaptor proteins such as growth factor receptor-bound protein-2 play important roles in cancer cell signaling.
A newly discovered endometrial (uterine) cancer biomarker and diagnostic method will enable detection of the tumor type that is likely to spread and recur so that clinicians can initiate treatment early and stop the cancer from attacking other parts of the body.
Many cells in the inner lining of the uterus carry 'cancer-driving' mutations that frequently arise early in life, report scientists from the Wellcome Sanger Institute, the University of Cambridge and their collaborators.
Women who don't survive a rare and aggressive uterine cancer called uterine serous carcinoma, have high expression of a group of 73 genes, a score scientists say can help identify these women and improve their outcome.
The risk of uterine endometrial cancer is increased by 24 gene variants that code for different cellular processes such as cell growth and death, gene regulation, and estrogen metabolism, according to a comprehensive review published in the Journal of Medical Genetics.
A new study reveals the molecular steps that bring about endometrial cancer, commonly known as uterine cancer, which is the sixth most common cancer in women across the globe.
A study published Feb. 13 in Cell provides an unprecedented look at the dozens of molecular steps that occur to bring about endometrial cancer, commonly known as uterine cancer.
The hormone estrogen plays many critical roles in men and women, in both healthy tissues and in cancer. In breast and gynecologic cancers, estrogen sends signals to tumors instructing the cancer cells to grow out of control.
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Nearly 50% of menopausal women complain of vaginal dryness, itching, and burning, among other commonly reported menopause symptoms. Laser therapy is one of the newer techniques for addressing these problems.
Obesity rates around the globe are ballooning - literally! Approximately 1.9 billion adults who are 18 years and older were overweight in 2016, and of these, more than 650 million were obese. The number of obese people has nearly tripled since 1975.